Boris Djordjevic
Founder, Healthspan Ventures
Founder of the 199 group of companies, building across longevity biotechnology, diagnostics, preventive medicine, and AI-enabled company creation.
Healthspan Ventures
We invest in companies that make humans live longer, think better, recover faster, and build at machine speed.
Healthspan Ventures is an early-stage deep-tech fund backing AI-native companies advancing radical healthspan, biological resilience, scientific automation, and human performance.
AI-native biotech
Longevity therapeutics
Scientific automation
Human performance
Investment risk warning: don't invest unless you're prepared to lose all the money you invest. This website is for information only and is not a public offer, investment advice, or a recommendation.
What we do
Venture capital for the next operating system of human biology.
Healthspan Ventures is an early-stage deep-tech fund backing frontier companies at the edge of AI, biotechnology, healthspan, and human enhancement. We invest in transformative founders building technologies that can extend healthy life, compress scientific discovery, and upgrade the human condition.
Our model combines venture capital with an applied intelligence platform. Beyond capital, we provide hands-on company-building support: AI infrastructure, scientific intelligence, brand strategy, strategic partnerships, and global network access.
Applied intelligence platform
We help portfolio companies become AI-native from inception.
The fund is not just a cheque. It is an operating layer for scientific founders who need speed, clarity, credibility, and follow-on readiness.
Scientific intelligence
We help founders turn biological complexity into crisp diligence, defensible milestones, and stronger technical narratives.
AI-native operations
We support automation across literature review, experiment design, market mapping, investor research, and internal workflows.
Capital readiness
We refine fundraising stories, data rooms, KPI architecture, follow-on strategy, and board-level communications.
Strategic network
We connect companies to scientific advisors, commercial partners, clinical operators, distribution channels, and global investors.
Investment thesis
Radical healthspan, biological resilience, scientific automation, and human performance.
We seek founders working at the edge of what is technically possible - from AI-designed therapeutics and longevity biotech to diagnostics, regenerative medicine, cognitive enhancement, and infrastructure for accelerated science.
AI-designed therapeutics
Longevity biotechnology
Diagnostics and biomarkers
Regenerative medicine
Cognitive enhancement
Scientific automation
Human performance
Research infrastructure
Built for technical founders before the market understands them.
We invest early
Pre-seed and seed companies with a credible technical wedge, ambitious market, and unusually strong founder-market insight.
We sharpen diligence
Scientific claims, regulatory path, translational risk, competition, and IP posture are turned into investable clarity.
We prepare the next round
We help founders build investor-grade narratives, data rooms, commercial proof, and follow-on syndicates.
Important regulatory note
Investment risk warning: don't invest unless you're prepared to lose all the money you invest. This website is for information only and is not a public offer, investment advice, or a recommendation.
Information on this website is not directed at the general public as an invitation to invest in any fund. Fund interests, if offered, would be made only through formal documentation to eligible investors and subject to applicable UK financial promotion and fund marketing rules.
Team
Stephanie Chen
Founding General Partner
Investor and ecosystem builder at the intersection of longevity, capital, wellness, and global strategic partnerships.
Antonia Schultze-Mosgau
Founding General Partner
Scientist and serial entrepreneur translating longevity research, AI, cognitive science, and preventive health into investable companies.